Neurology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Menstrually associated migraine (MAM) is often prolonged and difficult to manage with conventional therapies. Frovatriptan is a new selective 5HT(1B/1D) receptor agonist indicated for short-term management of migraine. It has a long half-life and good tolerability. These characteristics suggest that frovatriptan may be useful for the intermittent prevention of MAM. ⋯ Frovatriptan given prophylactically for 6 days was effective in reducing the incidence of menstrually associated migraine. More than half of patients who used frovatriptan 2.5 mg BID had no menstrually associated migraine headache during the 6-day perimenstrual period. The findings are consistent with the long duration of action and good tolerability of frovatriptan observed in short-term migraine management.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling.
To report results of a randomized pilot clinical feasibility trial of endovascular cooling in patients with ischemic stroke. ⋯ Induced moderate hypothermia is feasible using an endovascular cooling device in most patients with acute ischemic stroke. Further studies are needed to determine if hypothermia improves outcome.